PMID: 2498946Jan 1, 1989Paper

Effects of serotonin receptor antagonists on PAG stimulation induced aversion: different contributions of 5HT1, 5HT2 and 5HT3 receptors

Psychopharmacology
F JenckA M Van Delft

Abstract

The effects of serotonin receptor antagonists with differential selectivity for the various classes of 5HT receptors (5HT1, 5HT2 and 5HT3) were tested for their effects on the response to aversive brain stimulation. Electrical stimulation was administered to the dorsal part of the periaqueductal gray matter (PAG), one of the main cerebral structures subserving negative reinforcement. Stimulation frequency thresholds for escape responses were recorded before and following administration of the compounds. Ketanserin (0.32-32 mg/kg IP), trazodone (1.0-22 mg/kg), pirenperone (0.032-1.0 mg/kg) and spiperone (0.1-0.2 mg/kg) dose-dependently increased stimulation frequency thresholds necessary to induce escape responses. Opposite effects were observed with mianserin (0.01-32 mg/kg) and metergoline (0.032-10 mg/kg) which decreased threshold for escape. ICS 205-930 (0.01-10 mg/kg), did not affect the stimulation frequency threshold for escape. Prazosin (0.1-22 mg/kg) did not specifically affect aversive brain stimulation. Haloperidol (0.02-1.0 mg/kg) increased the frequency threshold for escape responses but with some motoric side effects. These data show that the various types of 5HT receptors differentially contribute to the control o...Continue Reading

References

Oct 25, 1977·Naunyn-Schmiedeberg's Archives of Pharmacology·P A Baumann, L Maître
Jul 1, 1978·Pharmacology, Biochemistry, and Behavior·R S KiserR M Lebovitz
Sep 1, 1978·Pharmacology, Biochemistry, and Behavior·L C Schenberg, F G Graeff
Mar 1, 1987·Naunyn-Schmiedeberg's Archives of Pharmacology·D HoyerH Davies
Apr 1, 1988·British Journal of Pharmacology·B J JonesM B Tyers
Jun 1, 1986·Naunyn-Schmiedeberg's Archives of Pharmacology·H Lemoine, A J Kaumann
Nov 4, 1986·European Journal of Pharmacology·G SandriniG Nappi
Jan 1, 1987·Psychopharmacology·M A Critchley, S L Handley
Jan 1, 1985·Psychopharmacology·M T SchützF G Graeff
Jun 1, 1985·Pharmacology, Biochemistry, and Behavior·S D Mendelson, B B Gorzalka
Mar 31, 1987·European Journal of Pharmacology·H H Berendsen, C L Broekkamp
Jan 1, 1985·Psychopharmacology·F G GraeffI G Karniol
May 1, 1986·Journal of Neurochemistry·P A Blurton, M D Wood
Jan 1, 1969·Journal of Neurosurgery·B S NasholdD G Slaughter
Aug 3, 1984·European Journal of Pharmacology·F C Colpaert, P A Janssen
Jan 1, 1983·British Journal of Clinical Pharmacology·R J Marshall
Sep 1, 1984·Pharmacology, Biochemistry, and Behavior·P BovierK G Lloyd
Dec 1, 1984·Neuropharmacology·S J Peroutka
May 1, 1984·Neuropharmacology·R W FullerM L Cohen
May 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·J R Fozard
Dec 1, 1984·Neuropharmacology·J R Fozard
Aug 1, 1983·Pharmacology, Biochemistry, and Behavior·F JenckP Karli
Nov 1, 1983·Pharmacology, Biochemistry, and Behavior·O G BergeK Hole
Oct 1, 1983·Physiology & Behavior·A P CarobrezF G Graeff
Jun 16, 1982·European Journal of Pharmacology·P M LaduronJ E Leysen
Jan 1, 1981·Behavioural Brain Research·P SchmittP Karli
Dec 1, 1980·Neuropharmacology·S Clements-JeweryL J Chidley
Feb 1, 1981·Journal of Neurochemistry·M HamonJ Glowinski
Dec 1, 1954·The American Journal of Physiology·J M DELGADON E MILLER
Apr 1, 1963·The Journal of Comparative Neurology·M E OLDS, J OLDS
Dec 1, 1963·International Journal of Neuropharmacology·M E OLDS, J OLDS

❮ Previous
Next ❯

Citations

Jun 16, 2004·Psychopharmacology·Andras Bilkei-GorzoAndreas Zimmer
Feb 27, 1990·European Journal of Pharmacology·F JenckA M Van Delft
Jun 1, 1995·Pharmacology, Biochemistry, and Behavior·G GriebelR J Blanchard
Sep 1, 1995·Pharmacology, Biochemistry, and Behavior·R L Nogueira, F G Graeff
Jun 1, 1996·Pharmacology, Biochemistry, and Behavior·G GriebelR J Blanchard
Apr 1, 1995·Pharmacology & Therapeutics·S L Handley
Dec 20, 1993·Behavioural Brain Research·F G GraeffR M Oliveira
Jan 1, 1990·Progress in Neuro-psychopharmacology & Biological Psychiatry·R ShanbhogueS Munonyedi
Feb 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·G GriebelR J Blanchard
Aug 1, 1995·Progress in Neurobiology·M M Behbehani
Jan 4, 1998·Pharmacology, Biochemistry, and Behavior·P O MoraF G Graeff
May 30, 2001·Neuroscience and Biobehavioral Reviews·D C BlanchardR J Blanchard
Jan 7, 1998·Neuroscience and Biobehavioral Reviews·F G GraeffP O Mora
Jul 15, 1998·Neuroscience and Biobehavioral Reviews·Y Clement, G Chapouthier
Mar 9, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B OlivierW Soudijn
Oct 24, 2006·Genes, Brain, and Behavior·M A De Souza SilvaE Dere
Jan 6, 2007·Psychopharmacology·Luciana Chrystine OliveiraMarcus Lira Brandão
Jul 1, 2009·Autonomic Neuroscience : Basic & Clinical·Gislaine G PelosiFernando M A Corrêa
Dec 14, 2007·Pharmacology, Biochemistry, and Behavior·Ana Carolina BroizMarcus Lira Brandão
Jul 3, 2007·Frontiers in Neuroendocrinology·Joseph S Lonstein
Jul 11, 2006·Pharmacology, Biochemistry, and Behavior·Dimitris E EmmanouilRaymond M Quock
Dec 6, 2005·European Journal of Pharmacology·Rosa M M de AlmeidaKlaus A Miczek
Jul 16, 2013·Behavioural Brain Research·Magda C TelesRui F Oliveira
Dec 3, 2010·Brain Research·Milena Vieira DeolindoFernando Morgan Aguiar Corrêa
Jan 1, 1991·Journal of Psychopharmacology·R J Rodgers
Aug 1, 1994·The International Journal of Neuroscience·S VlajkovićB D Janković

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here